Bristol-myers Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BRISTOL-MYERS, and when can generic versions of BRISTOL-MYERS drugs launch?
BRISTOL-MYERS has six approved drugs.
There are twenty-one US patents protecting BRISTOL-MYERS drugs.
There are three hundred and eighty-seven patent family members on BRISTOL-MYERS drugs in forty-five countries and fifty-five supplementary protection certificates in eighteen countries.
Summary for Bristol-myers
International Patents: | 387 |
US Patents: | 21 |
Tradenames: | 6 |
Ingredients: | 6 |
NDAs: | 6 |
Patent Litigation for Bristol-myers: | See patent lawsuits for Bristol-myers |
PTAB Cases with Bristol-myers as patent owner: | See PTAB cases with Bristol-myers as patent owner |
Drugs and US Patents for Bristol-myers
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bristol-myers | THALOMID | thalidomide | CAPSULE;ORAL | 020785-003 | Jan 17, 2003 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Bristol-myers | ISTODAX | romidepsin | POWDER;INTRAVENOUS | 022393-001 | Nov 5, 2009 | AP | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Bristol-myers | ABRAXANE | paclitaxel | POWDER;INTRAVENOUS | 021660-001 | Jan 7, 2005 | AB | RX | Yes | Yes | 9,511,046*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
Bristol-myers | VIDAZA | azacitidine | POWDER;INTRAVENOUS, SUBCUTANEOUS | 050794-001 | May 19, 2004 | AP | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Bristol-myers Squibb | DAKLINZA | daclatasvir dihydrochloride | TABLET;ORAL | 206843-003 | Apr 13, 2016 | DISCN | Yes | No | 9,421,192 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Bristol-myers Squibb | DAKLINZA | daclatasvir dihydrochloride | TABLET;ORAL | 206843-001 | Jul 24, 2015 | DISCN | Yes | No | 8,900,566 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Bristol-myers | INREBIC | fedratinib hydrochloride | CAPSULE;ORAL | 212327-001 | Aug 16, 2019 | RX | Yes | Yes | 7,528,143 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Bristol-myers
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bristol-myers | THALOMID | thalidomide | CAPSULE;ORAL | 020785-004 | Jan 10, 2007 | 7,874,984 | ⤷ Try a Trial |
Bristol-myers | THALOMID | thalidomide | CAPSULE;ORAL | 020785-001 | Jul 16, 1998 | 6,235,756 | ⤷ Try a Trial |
Bristol-myers | THALOMID | thalidomide | CAPSULE;ORAL | 020785-004 | Jan 10, 2007 | 6,908,432 | ⤷ Try a Trial |
Bristol-myers | THALOMID | thalidomide | CAPSULE;ORAL | 020785-001 | Jul 16, 1998 | 6,315,720 | ⤷ Try a Trial |
Bristol-myers | THALOMID | thalidomide | CAPSULE;ORAL | 020785-001 | Jul 16, 1998 | 8,315,886 | ⤷ Try a Trial |
Bristol-myers | THALOMID | thalidomide | CAPSULE;ORAL | 020785-003 | Jan 17, 2003 | 8,204,763 | ⤷ Try a Trial |
Bristol-myers | THALOMID | thalidomide | CAPSULE;ORAL | 020785-003 | Jan 17, 2003 | 5,629,327 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for BRISTOL-MYERS drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Capsules | 200 mg | ➤ Subscribe | 2006-09-25 |
➤ Subscribe | For Injection Suspension | 100 mg/vial | ➤ Subscribe | 2015-12-11 |
➤ Subscribe | Capsules | 50 mg and 100 mg | ➤ Subscribe | 2006-12-18 |
➤ Subscribe | Capsules | 150 mg | ➤ Subscribe | 2014-02-03 |
➤ Subscribe | Injection | 10 mg/vial | ➤ Subscribe | 2013-11-05 |
International Patents for Bristol-myers Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Ukraine | 109411 | ⤷ Try a Trial |
Hong Kong | 1250006 | ⤷ Try a Trial |
Colombia | 6801724 | ⤷ Try a Trial |
European Patent Office | 2943192 | ⤷ Try a Trial |
South Korea | 20150108943 | ⤷ Try a Trial |
Denmark | 2552415 | ⤷ Try a Trial |
New Zealand | 541142 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Bristol-myers Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2049522 | C20150003 00128 | Estonia | ⤷ Try a Trial | PRODUCT NAME: DAKLATASVIIR;REG NO/DATE: EU/1/14/939 26.08.2014 |
0961612 | 132009901771196 | Italy | ⤷ Try a Trial | PRODUCT NAME: PACLITAXEL(ABRAXANE); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/07/428/001, 20080114 |
2049522 | CR 2015 00003 | Denmark | ⤷ Try a Trial | PRODUCT NAME: DACLATASVIR OG FARMACEUTISK ACCEPTABLE SALTE DERAF, SAERLIGT DACLATASVIR-DIHYDROCHLORID; REG. NO/DATE: EU/1/14/939 20140826 |
1853250 | 300673 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: PACLITAXEL, GEFORMULEERD ALS ALBUMINE-GEBONDEN NANODEELTJES; REGISTRATION NO/DATE: EU/1/07/428/001-002 20131220 |
0961612 | 2009C/046 | Belgium | ⤷ Try a Trial | PRODUCT NAME: PACLITAXEL ALBUMIN; AUTHORISATION NUMBER AND DATE: EU/1/07/428/001 20080111 |
2049522 | 9/2015 | Austria | ⤷ Try a Trial | PRODUCT NAME: DECLATASVIR; REGISTRATION NO/DATE: EU/1/14/939 (MITTEILUNG) 20140826 |
1853250 | 37/2014 | Austria | ⤷ Try a Trial | PRODUCT NAME: PACLITAXEL, DAS ALS ALBUMIN GEBUNDENE NANOPARTIKEL FORMUIERT IST.; REGISTRATION NO/DATE: EU/1/07/428 (MITTEILUNG) (GEAENDERT DURCH C(2013) 9835) 20131230 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.